Drug intelligence / Profile preview

fulvestrant + sapanisertib

Development stage: Phase 2
Lead developer: Takeda
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

Combination therapy consisting of fulvestrant and sapanisertib. Fulvestrant is an estrogen receptor antagonist, while sapanisertib is a selective dual inhibitor of mTOR complexes 1 and 2 (TORC1 and TORC2). This combination was investigated for the treatment of estrogen receptor-positive (ER+)/HER2-negative advanced or metastatic breast cancer in postmenopausal women who experienced disease progression during or after aromatase inhibitor treatment. The combination aims to overcome endocrine resistance by simultaneously targeting the estrogen receptor pathway and the PI3K/AKT/mTOR signaling pathway.

Other names: FTH-003FTH003FTH 003HY-13328HY13328HY 13328CB-228CB228CB 228

Targets

ESR1 (ERα)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2

Beyond the preview

Go deeper on fulvestrant + sapanisertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + sapanisertib.